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A B S T R A C T
PINK1 codes for a serine/threonine-protein kinase located in the mitochondria. This protein contributes in the
pathophysiology of both neurodegenerative diseases and cancer. Its transcription has been shown to be regulated
by a natural occurring antisense (AS) RNA named PINK1-AS. We examined expression levels of PINK1 and
PINK1-AS in 54 breast cancer specimens versus their nearby non-cancerous tissues. We found significant down-
regulation of PINK1 in tumoral tissues compared with nearby tissues (P = .003). Yet, expression of PINK1-AS
was not remarkably different between tumoral tissues and nearby tissues. Relative expression of PINK1 was
associated with mitotic rate (P= .03). We also found trends toward over-expression of PINK1 in younger patient
compared with older patients (P = .09) and in grade 2 tumors compared with grade 3 ones (P = .08). The
current study delivers further evidences for contribution of PINK1 in the pathophysiology of breast cancer and
highlights the context-dependent properties the encoded protein.
1. Introduction
PTEN-induced putative kinase 1 (PINK1) codes for a serine/threonine-
protein kinase which is located in the cell mitochondria (Unoki and
Nakamura, 2001). The protein has prosurvival role at neuronal mi-
tochondria. Germline mutations within this gene have been linked with
heritable Parkinson's disease which is manifested in young persons
(Berthier et al., 2011). Moreover, PINK1 over-expression has been de-
tected in cancer cell lines with higher metastatic capability. Notably, its
sequence homology with the BRCA1-binding protein (BRAP2)
(Nakajima et al., 2003) implies its contribution in BRCA1 related
pathways. In silico assessment of cancer datasets has shown PINK1
over-expression in a fraction of kidney, endometrial, blood and para-
thyroid cancers despite its down-regulation in numerous other cancers
such as ovarian and liver carcinomas. Such different patterns of PINK1
expression between human malignancies suggest that PINK1 might
have a dual anti- and pro-tumorigenic capacities based on the tumor
environment (O'Flanagan and O'Neill, 2014). The PINK1 gene resides
on chromosome 1p36 (Valente et al., 2001), in a location which is re-
peatedly lost in a wide spectrum of malignancies and has been
suggested to contain one or several tumor suppressors (Bagchi and
Mills, 2008). A previous study has demonstrated cytoplasmic diffuse
PINK1 expression as well as a noticeable membrane expression in breast
carcinoma cells in contrast to the granular cytoplasmic pattern and the
low membrane expression detected in normal breast tissue specimens
(Berthier et al., 2011). In MCF-7 breast cancer cells, PINK1 has anti-
apoptotic and growth-suppressive functions (Berthier et al., 2011). The
observed anti-apoptotic effects of PINK1 in MCF-7 is in contrast with
the most noticeable property of PINK1 as a gene whose expression is
triggered by up-regulation of PTEN (Unoki and Nakamura, 2001) and
down-regulates the PI3-kinase (PI3K)/Akt signaling. However, despite
these characteristics, overexpression of the PINK1 transcript did not
suppress cell growth in some studied cancer cell lines (Unoki and
Nakamura, 2001). PINK1-antisense (PINK1-AS) is a naturally occurring
non-coding antisense (NAT) which has a nucleotide sequence homology
to the region that encodes C-terminus regulatory domain of PINK1. This
NAT has been shown to positively regulate the quantity of its cis-
transcribed mRNA under normal conditions (Scheele et al., 2007). Ac-
cording to the proposed roles for NATs in the modulation of gene ex-
pression and their participation in a variety of cancers (Nikpayam et al.,
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2017), and the putative role of PINK1 in the pathogenesis of breast
cancer, we aimed to assess expression of PINK1 and PINK1-AS in breast
cancer samples compared with their nearby non-cancerous tissues.
2. Material and methods
2.1. Samples
We performed expression analysis on 54 breast cancer samples and
their paired nearby tissues. All patients had been diagnosed to have
invasive ductal carcinoma. Subjects were diagnosed using the criteria
provided by World Health Organization (Sinn and Kreipe, 2013). Spe-
cimens were gathered from Sina and Farmanieh Hospitals during 2018,
snap frozen in liquid Nitrogen and carried to Department of Medical
Genetics for expression analysis. All patients were newly diagnosed
patients. No patients had taken any treatment such as neoadjuvant
chemotherapy or radiotherapy before surgical excision. All patients
signed the informed consent forms. The study protocol was approved by
the Ethical Committee of Shahid Beheshti University of Medical Sci-
ences. Hormone receptors and HER2 status have been gauged by im-
munohistochemistry strategy based on the guidelines and re-
commendations provided by the American Society of Clinical
Oncology/College of American Pathologists (Wolff et al., 2007;
Hammond et al., 2010). Nearby tissues were confirmed to be devoid of
the malignant cells by the expert specialist.
2.2. Expression analysis
RNA extraction and cDNA synthesis were perfomed by using the
TRIzol™ material (Invitrogen, Carlsbad, CA, USA) and cDNA Synthesis
Kit (TaKaRa, Japan), respectively. Transcript levels of PINK1 and
PINK1-AS genes were measured in tumoral tissues versus nearby tissues
using TaqMan Master Mix (Applied Biosystems). All experiments were
executed in the rotor gene 6000 Corbett System in duplicate.
Expressions of PINK1 and its NAT were normalized with the expression
of the housekeeping gene Hypoxanthine-guanine phosphoribosyl trans-
ferase 1 (HPRT1). The information about primers and probes are dis-
played in Table 1. PCR efficiency and threshold cycle (Ct) quantities
were used for quantification of RNA levels of each gene in tumoral
tissues and nearby tissues.
2.3. Statistical analysis
Statistics were investigated using the Statistical Package for the
Social Sciences (SPSS) v.20.0 (SPSS Inc., Chicago). The association
between clinical aspects and relative expression of PINK1 and its NAT
was evaluated using Chi-square. Tukey's honest significance test was
applied to investigate the variance between means of RNA levels be-
tween different sets of cases. Fold changes of expressions were quan-
tified using the efficiency adjusted strategies. Correlation between re-
lative transcripts levels of PINK1 and its NAT was weighed using the
regression model. The level of significance was judged at P < .05. The
receiver operating characteristic (ROC) curve was depicted to estimate
the properness of transcript amounts for discriminating tumoral versus
nearby tissues.
3. Results
3.1. Overall aspects of breast cancer patients
Overall aspects of enrolled patients are demonstrated in Table 2.
3.2. Relative expression of PINK1 and PINK1-AS in breast cancer
specimens versus nearby tissues
PINK1 expression was meaningfully lower in malinant samples
compared with nearby tissues (Fold change = 0.19, P = .003).
However, expression of PINK-AS1 was not different between tumoral
tissues and nearby tissues (Fold change = 0.64, P = .36). Fig. 1 dis-
plays the relative expression of PINK1 and its NAT in malignant tissues
and nearby tissues as designated by –delta Ct amounts (CT reference gene-
Table 1
The nucleotide sequences of primers and probes used for assessment of expression of PINK1 and PINK1-AS genes.
Gene Nucleotide sequence of primers/ probes Length of primers/ probes Length of amplicon
HPRT1 F: AGCCTAAGATGAGAGTTC 18 88
R: CACAGAACTAGAACATTGATA 21
FAM -CATCTGGAGTCCTATTGACATCGC- TAMRA 24
PINK1 F: GGAGTATGGAGCAGTCACTTACAG 24 111
R: AGCAGCGGCACGGAAGAG 18
FAM-ACATCATCCGGGTTCTCCGCGCCT-TAMRA 24
PINK1-AS F: GGTCCACGCCTTCCAGCAG 19 165
R: TTCCTCGCATCTCCTGTTCCTG 20
FAM - CCGCCTCGCCGCCATGATGCTG -TAMRA 22
Table 2
Overall aspects of enrolled patients (ER: estrogen receptor, PR: progesterone
receptor).
Variables Values
Age (years) (mean ± SD) 51.79 ± 13.54 (29–81)
Menarche age (years) (mean ± SD) 13 ± 1.65 (10–18)
Menopause age (years) (mean ± SD) 44.91 ± 14.91 (38–60)
Primary pregnancy age (years) (mean ± SD) 18.04 ± 8.36 (14–32)
Breast feeding length (months) (mean ± SD) 41.62 ± 34.1 (3−120)
Positive family history for other cancers (%) 17%
Cancer stage (%)
I 30.8
II 28.8
III 30.8
IV 9.6
Grade (%)
I 17
II 49
III 34
Mitotic rate (%)
I 45.2
II 42.9
III 11.9
Maximum Tumor zdimention (%)
< 2 cm 32
≥2 cm, < 5 cm 66
≥5 cm 2
ER (%)
Positive 87.8
Negative 12.2
PR (%)
Positive 77.1
Negative 22.9
Her2/neu expression (%)
Positive 25
Negative 75
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CT target gene).
3.3. Association between expression of genes and tumor aspects
We assessed relative expression of PINK1 and its NAT in each ma-
lignant sample versus its paired nearby tissue and arranged patients to
down−/−up-regulated clusters for each gene based on these figures.
We successively gaged association between relative expression of these
genes and tumor aspects (Table 3). Relative expression of PINK1 was
associated with mitotic rate (P = .03).
We also compared normalized expression of PINK1 and PINK1-AS
between clinicopathological-based subdivisions and found trends to-
ward over-expression of PINK1 in younger patient compared with older
patients (P = .09) and in grade 2 tumors compared with grade 3 ones
(P = .08) (Table 4).
3.4. Correlation between expression of PINK1 and its NAT in breast cancer
samples and nearby tissues
We found substantial correlation between relative expressions of
PINK1 and its NAT in both malignant tissues and nearby tissues (Figs. 2
and 3). According to the R2 values, the correlation was strong in tu-
moral tissues (R2 = 0.89) and moderate in ANCTs (R2 = 0.35).
3.5. ROC curve analysis
ROC curve analysis showed 79.6% specificity and 51.9% sensitivity
for PINK1 transcript levels in discrimination of breast cancer tissues
from nearby tissues (Table 5 and Fig. 4).
4. Discussion
Several lines of evidences indicate similarities between cancer and
neurodegeneration especially in the terms of signaling pathways that
regulate cell survival and death and DNA damage repair (O'Flanagan
et al., 2016). PINK1 is among molecules that is involved in the patho-
physiology of both neurodegenerative conditions and malignancies
(O'Flanagan et al., 2016). This protein is originally designated based on
its stimulation by the tumor suppressor PTEN in malignant cells.
Meanwhile, it is a controller of cell cycle transition whose silencing
considerably decreased cell proliferation, colony formation and inva-
siveness in immortalized mouse embryonic fibroblasts (O'Flanagan
et al., 2015). However, overexpression of the PINK1 transcript did not
suppress cell growth in some studied malignant cell lines (Unoki and
Nakamura, 2001). On the other hand, PINK1 expression is both con-
trolled by and controls PI3K/Akt signaling which support its role in the
carcinogenesis process (O'Flanagan and O'Neill, 2014). The results of
previous studies suggest that PINK1 might have different or opposite
functions even in a certain type of malignancy as revealed by dual anti-
apoptotic and growth-inhibitory functions in breast cancer cells
(Berthier et al., 2011). According to the inconsistencies between former
studies regarding the role of PINK1 in the development of cancer, we
assessed its expression in breast tissue samples and demonstrated down-
regulation of PINK1 in invasive ductal carcinoma samples versus their
nearby tissues. Such observed down-regulation of PINK1 in tumoral
tissues of breast is consistent with the proposed role for it in the BRCA1
related pathways based on its sequence homology with BRAP2
(Nakajima et al., 2003). So, we hypothesize that its down-regulation
might mimic lack of BRCA1 expression in breast cancer cells. Future in
vitro studies are necessary to evaluate this assumption.
We simultaneously assessed expression of its NAT namely PINK1-AS
in the same cohort of patients and reported no difference in its ex-
pression between tumoral tissues and nearby tissues. PINK1-AS is a long
non-coding RNA which stabilizes its sense coding RNA (Scheele et al.,
2007). Such proposed role for PINK1-AS is supported by the observed
positive correlation between expression levels of PINK1 and PINK1-AS
in both tumoral tissues and nearby tissues. The stronger pairwise cor-
relation in tumoral tissues might reflect the occurrence of a novel
regulatory route to compensate the decrease in the PINK1 in tumoral
tissues which needs to be judged in upcoming investigations.
We detected an association between PINK1 expression and mitotic
rate which is in line with the suggested function of this gene in the
modulation of PI3K/Akt/mTOR signaling axis (O'Flanagan and O'Neill,
2014) and warrants functional studies to clarify the underlying me-
chanism and its practical application in cancer management. We also
found trends toward over-expression of PINK1 in younger patient
compared with older patients (P = .09) and in grade 2 tumors versus
grade 3 ones (P = .08). Supposing a tumor suppressor role for PINK1 in
breast cancer (as suggested by the observed reduction of it in tumoral
tissues compared with nearby tissues), higher expression of it in
younger patients and in lower grades might reflect higher levels of
PTEN expression in these subjects. Imminent investigations in larger
sample sizes are required to verify these associations, reveal the un-
derlying mechanism and assess its significance in patients' outcome.
As a final point, we measured the diagnostic power of PINK1 ex-
pression levels in breast tissues and demonstrated that it can predict the
presence of cancer with 79.6% specificity and 51.9% sensitivity. Based
on its high specificity, it might be a putative biomarker in a panel of
biomarkers for breast cancer.
Our study had some limitations. Although we only demonstrated
down-regulation of PINK1 in relation to the mitotic rate, a larger per-
centage of patients with down-regulation of this gene had a lower mi-
totic rate which is associated with higher survival. Therefore, it con-
fuses the presentation of the PINK1 as a contributor to breast cancer
pathogenesis. Furthermore, PINK1 showed no association with the
different molecular subtypes or tumor grade which adds to a conflicting
picture. Besides, although we hypothesized that down-regulation of this
gene might mimic lack of BRAC1 expression, we did not assess this
aspect in our data. We also did not assess other associated mechanistic
PINK1 markers. Thus, the current results are preliminary results
Fig. 1. Relative expression of PINK1 and its NAT in malignant tissues and
nearby tissues as designated by –delta CT amounts (CT reference gene-CT target
gene).
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Table 3
Association between relative expressions of genes in malignant tissues compared with nearby tissues and tumor features (For each parameter, there are different
numbers of missing data).
PINK1 up-regulation PINK1 down-regulation P value PINK1-AS1 up-regulation PINK1-AS1 down-regulation P value
Age 0.56 0.72
<55 years 11 (32.4%) 23 (67.6%) 12 (35.3%) 22 (64.7%)
≥55 years 5 (25%) 15 (75%) 8 (40%) 12 (60%)
Stage 0.07 0.6
1 4 (25%) 12 (75%) 5 (31.3%) 11 (68.7%)
2 3 (20%) 12 (80%) 4 (26.7%) 11 (73.3%)
3 3 (18.8%) 13 (81.2%) 6 (37.5%) 10 (62.5%)
4 4 (80%) 1(20%) 3 (60%) 2 (40%)
Histological grade 0.1 0.92
1 2 (25%) 6 (75%) 2 (25%) 6 (75%)
2 3 (13%) 20 (87%) 8 (34.8%) 15 (65.2%)
3 7 (43.8%) 9 (56.3%) 6 (37.5%) 10 (62.5%)
Mitotic rate 0.03 0.64
1 2 (10.5%) 17 (89.5%) 6 (31.6%) 13 (68.4%)
2 6 (33.3%) 12 (66.7%) 7 (38.9%) 11 (61.1%)
3 3 (60%) 2 (40%) 2 (40%) 3 (60%)
Tumor size 0.4 0.58
<2 4 (25%) 12 (75%) 6 (37.5%) 10 (62.5%)
2–5 9 (27.3%) 24 (72.7%) 11 (33.3%) 22 (66.7%)
>5 1 (100%) 0 (0%) 1(100%) 0 (0%)
ER status 0.33 0.65
Positive 11 (25.6%) 32 (74.4%) 15 (34.9%) 28 (65.1%)
Negative 3 (50%) 3 (50%) 3 (50%) 3 (50%)
PR status 0.11 0.46
Positive 8 (21.6%) 29 (78.4%) 11 (29.7%) 26 (70.3%)
Negative 5 (45.5%) 6 (54.5%) 6 (54.5%) 5 (45.5%)
Her2 status 0.71 0.6
Positive 4 (33.3%) 8 (66.7%) 5 (41.7%) 7 (58.3%)
Negative 9 (25%) 27 (75%) 12 (33.3%) 24 (66.7%)
Table 4
Association between expression quantities of genes in malignant tissues and clinical aspects (Mean (Standard deviation) values of Efficiency ^CT reference gene-
Efficiency ^CT target gene are displayed).
PINK1 expression P value PINK1-AS1 expression P value
Age
< 55 years old vs. ≥55 years old 7.12 (2.56) vs. 6.21 (1.81) 0.09 3406.35 (86.84.56) vs. 7424.23 (21,455.68) 0.34
ER status
ER(+) vs. ER(−) 4.19 (2.11) vs. 1.03 (2.52) 0.51 4166.08 (13,378.33) vs. 2086.09 (2719.47) 0.73
PR status
PR(+) vs. PR(−) 3.66 (2.17) vs. 9.73 (2.19) 0.42 2632.01 (8284.69) vs. 1726.18 (2373.62) 0.73
HER2 status
HER2 (+) vs. HER2 (−) 3.8 (1.29) vs. 5.47 (2.4) 0.82 830.67 (1894.92) vs. 3001.36 (8489.03) 0.38
Tumor grade
Grade 1 vs. 2 2.05 (3.05) vs. 4.23 (1.25) 0.9 9503.13 (16,191.96) vs. 1128.86 (2255.95) 0.21
Grade 1 vs. 3 2.05 (3.05) vs. 1.49 (3.63) 0.25 9503.13 (16,191.96) vs. 5371.4 (17,653.05) 0. 71
Grade 2 vs. 3 4.23 (1.25) vs. 1.49 (3.63) 0.08 1128.86 (2255.95) vs. 5371.4 (17,653.05) 0.55
y = 0.7787x - 0.3464
R² = 0.8988
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Fig. 2. Correlation between expression of PINK1 and its NAT in breast cancer
samples.
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Fig. 3. Correlation between expression of PINK1 and PINK1-AS in nearby tis-
sues.
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needing mechanistical verifications.
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